Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) is reporting second quarter financial results on Thursday 13th August 2020, after market close.
Previous Quarter Performance
Navidea Biopharmaceuticals, Inc. came out with loss for the first quarter of $ 0.13 per share, from the revenue of $ 0.16 million. The quarterly revenues compared with the same quarter last year. According to street consensus, revenue of was expected for the first quarter The bottom line results street analysts by $ 0.1 or , at the same time, top line results analysts by $ 3.19 million or .
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Navidea Biopharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of NAVB was $ 2.89, representing a 489.80 % increase from the 52 week low of $ 0.49 and a 46.08 % decrease over the 52 week high of $ 5.36.
The company has a market capital of $ 73.54 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”NAVB” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages.
